Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Berger

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Neurology|July 30, 2025
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple SclerosisAntoine Gavoille, Emmanuelle Leray, Romain Marignier, et al.
Advances in Therapy|February 19, 2025
LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in FranceJérôme de Sèze, Pierre Labauge, Roland Liblau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2022
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring systemCamille Sabathé, Romain Casey, Sandra Vukusic, et al.
JAMA Neurology|August 4, 2025
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Neurology|July 14, 2019
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosisDavid-Axel Laplaud, Romain Casey, Laetitia Barbin, et al.
Neurology|December 23, 2022
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal InferenceAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Neurology|July 16, 2025
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple SclerosisCamille Robin, Fabien Rollot, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosisAntoine Gavoille, Mikail Nourredine, Fabien Rollot, et al.
European Journal of Neurology|May 2, 2025
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM studyMikael Cohen, Fabien Rollot, Marc Debouverie, et al.
Brain : a Journal of Neurology|February 14, 2026
Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosisFabien Rollot, Romain Casey, Anne Kerbrat, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Neurology|July 30, 2025
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple SclerosisAntoine Gavoille, Emmanuelle Leray, Romain Marignier, et al.
Advances in Therapy|February 19, 2025
LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in FranceJérôme de Sèze, Pierre Labauge, Roland Liblau, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2022
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring systemCamille Sabathé, Romain Casey, Sandra Vukusic, et al.
JAMA Neurology|August 4, 2025
Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Neurology|July 14, 2019
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosisDavid-Axel Laplaud, Romain Casey, Laetitia Barbin, et al.
Neurology|December 23, 2022
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal InferenceAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
Neurology|July 16, 2025
Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple SclerosisCamille Robin, Fabien Rollot, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 4, 2025
Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosisAntoine Gavoille, Mikail Nourredine, Fabien Rollot, et al.
European Journal of Neurology|May 2, 2025
Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM studyMikael Cohen, Fabien Rollot, Marc Debouverie, et al.
Brain : a Journal of Neurology|February 14, 2026
Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosisFabien Rollot, Romain Casey, Anne Kerbrat, et al.
Pageof 13